Drug profile · INN
donanemab-azbt
KISUNLA
donanemab-azbt (KISUNLA) is a amyloid-beta a4 protein disrupting agent. Route of administration: injection. Current US regulatory status: approved.
Drug details — donanemab-azbt
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
donanemab-azbt (KISUNLA) is a amyloid-beta a4 protein disrupting agent. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Amyloid-beta A4 protein disrupting agent
Primary target: Amyloid-beta precursor protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Recent coverage
Related & competitor drugs
Frequently asked questions
What is donanemab-azbt?
donanemab-azbt (KISUNLA) is a amyloid-beta a4 protein disrupting agent. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for donanemab-azbt?
KISUNLA is a marketed brand name for donanemab-azbt. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of donanemab-azbt?
donanemab-azbt has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.